The FDA levied import alerts on 49 manufacturing sites in fiscal year 2021 for refusing inspections or records requests, noncompliant laboratory testing and noncompliant findings from inspections and records requests — a marked decrease over a high of 128 import alerts issued in fiscal year 2020.
Source: Drug Industry Daily